Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

 
• By Cathy Kelly
  
regulatory compliance concept on the gearwheels, 3D rendering
Compliance Challenge Underway In 340B Program

More from Pricing Debate

More from Market Access